TrialThe Lancet. Oncology2016

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

David Dearnaley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.